Title: Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the
treatment of chronic hepatitis C: the real-world data in China
Version: 0 Date: 10 Jul 2023
Reviewer:  Chun-Ming Hong
Reviewer's report:
Nice work, congratulations!
I have some comments and questions:
Comments:
1. In Line 37 of Abstract, “real word study” should be “real world study”.
2. What are the percentages of HBV co-infection in ECS and DNV groups?
3. What are the percentages of HIV co-infection in ECS and DNV groups?
Title: Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the
treatment of chronic hepatitis C: the real-world data in China
Version: 0 Date: 10 Jul 2023
Reviewer:  Chun-Ming Hong
Reviewer's report:
Nice work, congratulations!
I have some comments and questions:
Comments:
1. In Line 37 of Abstract, “real word study” should be “real world study”.
2. What are the percentages of HBV co-infection in ECS and DNV groups?
3. What are the percentages of HIV co-infection in ECS and DNV groups?
Please review this paper.
user
Title: Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the
treatment of chronic hepatitis C: the real-world data in China
Version: 0 Date: 10 Jul 2023
Reviewer:  Chun-Ming Hong
Reviewer's report:
Nice work, congratulations!
I have some comments and questions:
Comments:
1. In Line 37 of Abstract, “real word study” should be “real world study”.
2. What are the percentages of HBV co-infection in ECS and DNV groups?
3. What are the percentages of HIV co-infection in ECS and DNV groups?
assistant